1607005-15-1

Basic information

• Product Name: N-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzyl)-4-(tert-butyl)benzamide
• Synonyms: N-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzyl)-4-(tert-butyl)benzamide
• CAS NO: 1607005-15-1
• Molecular Weight: 384.481
• Mol File: 1607005-15-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzyl)-4-(tert-butyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzyl)-4-(tert-butyl)benzamide(1607005-15-1)
• EPA Substance Registry System: N-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzyl)-4-(tert-butyl)benzamide(1607005-15-1)

Safety Data

• Hazardous Substances Data: 1607005-15-1(Hazardous Substances Data)

Upstream product

• 98-73-7 4-(1,1-dimethylethyl)benzoic acid 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 479633-63-1 4-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 1607005-81-1 {4-[7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzyl}carbamic acid tert-butyl ester 
• 877131-77-6 2-(4-bromo-2-ethylbenzyl)isoindoline-1,3-dione 
• 877131-21-0 (4-bromo-2-ethylphenyl)methanol 
• 644984-78-1 4-bromo-2-ethylbenzoic acid 
• 1255636-51-1 (4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)methanamine 
• 1607005-55-9 [4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-benzyl]-carbamic acid tert-butyl ester 
• 330794-35-9 tert-butyl N-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]carbamate 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases

Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine producti

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with exc